Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2021-09-07 19:04 5845

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...

2021-09-07 19:00 3576

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

- Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placeb...

2021-09-07 18:00 4462

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited announced the appointment ofGiuliano Perfetti as its Chief Executive Officer. Mr. Giuliano Perfetti joins as CEO Jubilant Bio...

2021-09-07 16:11 6055

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

* The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally * Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, g...

2021-09-06 19:03 6016

GenScript ProBio Enters into Agreement with SYNIMMUNE for Manufacturing of their Innovative Antibody Drug

NANJING, China, Sept. 6, 2021 /PRNewswire/ -- GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production. FLYSYN is a fms-like tyrosine kinase 3 (FLT3) specific antibody for the ...

2021-09-06 16:00 3594

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...

2021-09-06 13:44 4560

Kintor Pharma Included in Hong Kong Stock Connect Program

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hong Kong Stock Conn...

2021-09-06 11:30 4722

CStone Pharmaceuticals Included in the Hong Kong Stock Connect

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, announced that the Company has been...

2021-09-06 11:30 4973

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

SUZHOU, China, Sept. 5, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1...

2021-09-06 09:00 1987

AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases

BEIJING, Sept. 5, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, announced during the recent "China International Trade in Servi...

2021-09-06 08:00 1786

WuXi AppTec Receives AA ESG Rating from MSCI

SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...

2021-09-06 08:00 3676

WuXi AppTec Receives AA ESG Rating from MSCI

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

DAEJEON, South Korea, Sept. 3, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II c...

2021-09-03 20:00 2584

Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets

SHANGHAI and NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end AI-powered drug discovery company, today announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical pipeline assets. Dr. Spiegel brings over 35 years of exte...

2021-09-02 21:00 4361

I-Mab Added to FTSE Russell Global Equity Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Eq...

2021-09-02 20:00 6694

Elekta acquires Turkish distributor to strengthen market position

STOCKHOLM, Sept. 2, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has acquired its long-time partner and Turkish distributor of neurosurgery solutions, Özyürek Mümessillik ve Dış Ticaret A.Ş. (Özyürek A.Ş.). The acquisition will improve Elekta's market access in the region and ...

2021-09-02 14:16 4953

CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy * The new drug applic...

2021-09-02 08:05 4726

Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline

HONG KONG, Sept. 1, 2021 /PRNewswire/ -- Insilico Medicine is pleased to announce an R&D collaboration with Gray Matter, a longevity biotechnology company focused on peptide-based interventions against cognitive decline, age-related CNS diseases, and aging. This strategic partnership is intended ...

2021-09-01 22:08 3951

Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline

Seegene Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four COVID-19 Diagnostic Tests

SEOUL, South Korea, Sept. 1, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced on August 20 that it has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays. Combo Swab is a user-friendly...

2021-09-01 17:40 2347

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell onAugust 31. Jacobio will collaborate with Hebecell to develop thenext-generation natural killer cell therapy based...

2021-08-31 22:05 5846

1 ... 329 330 331332333 334 335 ... 343